Laboratory of Infectious Diseases

Established in 1942, the NIAID Laboratory of Infectious Diseases (LID) has a long history of discovering new agents of viral diseases and developing innovative vaccines and treatments such as FluMist, a nasal spray influenza vaccine; Synagis, a preventative treatment for respiratory syncytial virus; and Havrix, a hepatitis A vaccine licensed by GlaxoSmithKline.

Clinical Trials Sponsored by the Laboratory of Infectious Diseases Clinic

The clinical trials and studies conducted by the Laboratory of Infectious Diseases Clinical Research Program change frequently, but you can see a list of all current clinical trials and studies being conducted by the Laboratory of Infectious Diseases Clinic on our Find a Clinical Trial page.

View Trials

The LID Clinical Studies Unit (LID CSU) seeks to perform translational research studies to answer fundamental questions regarding human influenza and other emerging viral infections to inform and impact future vaccine and therapeutic design, while also making an effort to assist in evaluation of novel products that may impact human health.

In recent years, the LID CSU has initiated efforts to perform uncommon and difficult, but necessary clinical studies to evaluate novel vaccines and therapeutics particularly universal influenza vaccines in the human challenge model and extremely novel universal vaccines for vector borne disease like Dengue, Zika, and Leishmaniasis.

Tour the Special Clinical Studies Unit

What is it Like to Participate?

Photo of Sara Jones

To me, science is better than magic. Through scientific research, we gain the ability to prevent or cure disease.

– Sara Jones

Contact Information

For questions about participating in clinical studies, contact:
Office of Patient Recruitment
Toll Free: 1-800-411-1222
TTY: 1-866-411-1010
Se habla español. Email:

Content last reviewed on